Thomas Moll

Dr. Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honours” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the University of Muenster, Germany, before joining Cardion AG, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation.